Long‐term outcomes following proton therapy for pediatric spinal low‐grade glioma
- 25 September 2024
- journal article
- research article
- Published by Wiley in Pediatric Blood & Cancer
- Vol. 71 (12) , e31341
Abstract
Background: Due to its rarity, no standard treatment guidelines exist for pediatric spinal low‐grade glioma (LGG‐S). Proton therapy (PT) offers an attractive modality to minimize toxicity. Herein, we present the first published series of pediatric patients who received PT for progressive LGG‐S. Procedures: We identified eight consecutive patients with nonmetastatic LGG‐S treated with PT. Cumulative incidence method was used to estimate local control (LC), freedom from distant metastases (FFDM), and freedom from progression (FFP). The Kaplan–Meier product limit method assessed overall survival (OS). Toxicity was assessed according to the Common Terminology Criteria for Adverse Events Version 5.0. Results: Median age at diagnosis was 4 years. All patients underwent attempted resection and developed recurrence/progression prior to referral for PT, with median duration between initial surgery and PT of 4.4 years. Median age at the start of PT was 8 years. Most patients ( n = 5) received PT as ≥third line treatment. Seven patients were treated with PT to the primary tumor. Most patients ( n = 7) received between 45–50.4 CGE. Median follow up was 7.8 years. The 10‐year estimates for LC, FFDM, FFP, and OS were 85, 88, 73, and 55%, respectively. One patient experienced malignant transformation and two developed pseudoprogression following PT. No pulmonary, gastrointestinal, or musculoskeletal toxicities were observed during or after PT. Conclusions: Despite negative selection bias our experience suggests PT for pediatric LGG‐S offers long‐term disease control with limited toxicity. The favorable therapeutic ratio of PT suggests it should be considered among first‐line therapy in children with nonmetastatic, unresectable LGG‐S.Keywords
This publication has 16 references indexed in Scilit:
- CBTRUS Statistical Report: Primary Brain and Other Central Nervous System Tumors Diagnosed in the United States in 2016—2020Neuro-Oncology, 2023
- Early and late contrast enhancing lesions after photon radiotherapy for IDH mutated grade 2 diffuse gliomaRadiotherapy and Oncology, 2023
- High frequency of disease progression in pediatric spinal cord low-grade glioma (LGG): management strategies and results from the German LGG study groupNeuro-Oncology, 2020
- Superior Intellectual Outcomes After Proton Radiotherapy Compared With Photon Radiotherapy for Pediatric MedulloblastomaJournal of Clinical Oncology, 2020
- Proton versus Photon Radiotherapy for Pediatric Central Nervous System Malignancies: A Systematic Review and Meta-Analysis of Dosimetric Comparison StudiesJournal of Oncology, 2019
- Outcomes Following Proton Therapy for Pediatric Low-Grade GliomaInternational Journal of Radiation Oncology - Biology - Physics (IJROBP), 2019
- Analysis of pseudoprogression after proton or photon therapy of 99 patients with low grade and anaplastic gliomaClinical and Translational Radiation Oncology, 2018
- Radiation Therapy for Optic Pathway and Hypothalamic Low-Grade Gliomas in ChildrenInternational Journal of Radiation Oncology - Biology - Physics (IJROBP), 2017
- Clinical Outcomes and Late Endocrine, Neurocognitive, and Visual Profiles of Proton Radiation for Pediatric Low-Grade GliomasInternational Journal of Radiation Oncology - Biology - Physics (IJROBP), 2014
- Nonperioperative strokes in children with central nervous system tumorsCancer, 2002